Navigation Links
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Date:2/5/2009

MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA).

The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every two weeks to patients with a diverse range of solid tumors. Safety and tolerability data from this study augments data obtained in the company's first Phase I study where CYT997 was administered intravenously. Together, these studies suggest that the CYT997 is a potent and selective VDA which is well tolerated at biologically efficacious doses and is worthy of further investigation as a novel anticancer agent.

"Cytopia has now demonstrated the broad clinical potential of CYT997 in both intravenous and oral forms," said Mr. Andrew Macdonald, CEO. "The oral activity of CYT997 is a key advantage over most other vascular disrupting agents which are administered intravenously. The oral activity of the agent should markedly improve its clinical and commercial value."

The company has already commenced Phase II studies for the intravenous form of CYT997 and intends to undertake similar efficacy studies for the oral presentation. Investigating the safety and efficacy of metronomic dosing, frequent oral administration at a comparatively low, but biologically effective dose, is of particular interest.

This oral trial was partly funded under the company's $A3 million Commercial Ready grant.

Preliminary trial data

CYT997 was generally well tolerated in this study with a maximum tolerated dose in cancer patients of ca 165 mg/m2. This dose resulted in maximal plasma concentrations some twofold higher than those obse
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytopia Scientific Presentations on JAK2 Inhibitor Program
2. Cytopia Commences Second Phase II Study in Brain Cancer
3. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
4. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
5. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
6. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
7. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
8. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
11. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... California , September 1, 2015 ... is segmented on the basis of sectors, products ... chronic diseases globally coupled with the increasing demand ... diseases are expected to propel the growth for ... manage biological information efficiently is known as bioinformatics. ...
(Date:9/1/2015)... Aug. 31, 2015 Research and Markets ( ... "Regulatory Affairs for Support Staff (London, UK - September ... This two day course provides an introduction to ... and has been designed specifically for those working in ... gain an overview of EU regulatory procedures required to ...
(Date:9/1/2015)... 2015 - The ... egistry data presented at ESC Congress ... the evolution of manag ing AF in ... -   The first-ever two-year outcomes from the Global Anticoagulant ... expose that all-cause death was the most frequent major event in more than ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
... U.S. Food and Drug Administration today approved Ferriprox (deferiprone) ... transfusions in patients with thalassemia, a genetic blood disorder ... prior chelation therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... iron in the body from the frequent blood transfusions ...
... SAN RAMON, Calif., Oct. 14, 2011 Armanino ... successful company-wide Microsoft Dynamics AX implementation and the ... MES (Manufacturing Engineering System) to streamline the production ... equipment.  Microsoft Dynamics AX is a comprehensive business ...
Cached Medicine Technology:FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 2FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 3Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 2Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 3
(Date:9/1/2015)... ... , ... Earth Brands, ( http://www.earthbrands.com ) a comfort-meets-fashion women’s ... buys an Earth Brand shoe will be given an opportunity to plant a ... a nonprofit dedicated to planting more trees. Earth Brands products represent contemporary designs ...
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy , ... partnership with Apex Physical Therapy (Apex) is official as of August ... compassionate, and empathetic care to local residents from their combined eight locations throughout ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... not managed, stress created from everyday life changes can lead to very serious, ... provide support for coping with stress. Herbal supplement manufacturer MediHerb has ...
(Date:9/1/2015)... ... 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive ... Camp Compass® has taken place at Kingsborough Community College in Brooklyn in each of ... work for Calvary, and two junior counselors who were campers themselves just a few ...
(Date:9/1/2015)... ... 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) has ... LATINA Style 50 Report that recognizes companies that provide the best career opportunities for ... climbs from number 24 to 21 of the 50 Best Companies for Latinas. The ...
Breaking Medicine News(10 mins):Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3
... with God, affects medical choices, study finds , FRIDAY, Dec. 18 ... cancer could be just as important as taking care of their ... what was important to them at the end of their lives, ... being at peace with God, the study found. , "Medicine ...
... ... the nostrils help deliver scent molecules into the nose to the olfactory bulb, where ... From there, they are forwarded to areas of the central nervous system that mediate ... ...
... ... used across a range of enterprise activities , ... Washington, D.C. (PRWEB) December 18, 2009 -- Applied Predictive Technologies ... in the world, has signed an agreement to license APT,s Test & Learn Management System. ...
... Make your ... certificates and his own name-brand prescription-strength line of skincare products for Christmas. ... Denver, CO (PRWEB) December 17, ... your shopping done! Online gift certificates are now available at www.ravalmd.com and ...
... , , NEW YORK, Dec. 17 The Hebrew University ... Tropical Diseases has received a $5 million grant from the ... The project will be led by Professor Alon Warburg, ... and will include experts from Hebrew University,s Robert H. Smith ...
... , ... , EDF calls for dirty heating oil phase out by 2020 ... of the city,s heating oil soot pollution is created by burning the dirtiest ... City, according to a new report released today by ...
Cached Medicine News:Health News:Spiritual Needs Rank High as Death From Cancer Nears 2Health News:Spiritual Needs Rank High as Death From Cancer Nears 3Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 2Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 3Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 4Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 5Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 6Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 7Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 8Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 9Health News:Banfield, The Pet Hospital Signs Agreement to License APT's Test & Learn Management System 2Health News:Banfield, The Pet Hospital Signs Agreement to License APT's Test & Learn Management System 3Health News:Streamline Your Holiday Shopping With Online Savings At Ravalmd.com 2Health News:Bill & Melinda Gates Foundation Grants $5 Million For Infectious Disease Research At The Hebrew University Of Jerusalem 2Health News:Bill & Melinda Gates Foundation Grants $5 Million For Infectious Disease Research At The Hebrew University Of Jerusalem 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 2Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 4
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: